|
1
|
Zainal Ariffin O and Nor Saleha IT:
Nationa. Cancer Registry Report 2007. Malaysia Cancer Statistics -
Data and Figure. National Cancer Registry, Ministry of Health,
Putrajaya Malaysia: 2011
|
|
2
|
Othman NH, Nor ZM and Biswal BM: Is
Kelantan joining the global cancer epidemic? - experience from
hospital Universiti Sains Malaysia; 1987–2007. Asian Pac J Cancer
Prev. 9:473–478. 2008.PubMed/NCBI
|
|
3
|
Farrell J, Petrovics G, McLeod DG and
Srivastava S: Genetic and molecular differences in prostate
carcinogenesis between African American and Caucasian American men.
Int J Mol Sci. 14:15510–15531. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mononen N and Schleutker J: Polymorphisms
in genes involved in androgen pathways as risk factors for prostate
cancer. J Urol. 181:1541–1549. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rosen P, Pfister D, Young D, et al:
Differences in frequency of ERG oncoprotein expression between
index tumors of Caucasian and African American patients with
prostate cancer. Urology. 80:749–753. 2012. View Article : Google Scholar
|
|
6
|
Martin DN, Starks AM and Ambs S:
Biological determinants of health disparities in prostate cancer.
Curr Opin Oncol. 25:235–241. 2013.PubMed/NCBI
|
|
7
|
Amundadottir LT, Sulem P, Gudmundsson J,
et al: A common variant associated with prostate cancer in European
and African populations. Nat Genet. 38:652–658. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Freedman ML, Haiman CA, Patterson N, et
al: Admixture mapping identifies 8q24 as a prostate cancer risk
locus in African-American men. Proc Natl Acad Sci USA.
103:14068–14073. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Taioli E, Sears V, Watson A, et al:
Polymorphisms in CYP17 and CYP3A4 and prostate cancer in men of
African descent. Prostate. 73:668–676. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rubin MA, Maher CA and Chinnaiyan AM:
Common gene rearrangements in prostate cancer. J Clin Oncol.
29:3659–3668. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rosen P, Sesterhenn IA, Brassell SA,
McLeod DG, Srivastava S and Dobi A: Clinical potential of the ERG
oncoprotein in prostate cancer. Nat Rev Urol. 9:131–137. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Magi-Galluzzi C, Tsusuki T, Elson P, et
al: TMPRSS2-ERG gene fusion prevalence and class are significantly
different in prostate cancer of Caucasian, African-American and
Japanese patients. Prostate. 71:489–497. 2011. View Article : Google Scholar
|
|
13
|
Lee K, Chae JY, Kwak C, Ku JH and Moon KC:
TMPRSS2-ERG gene fusion and clinicopathologic characteristics of
Korean prostate cancer patients. Urology. 76(1268): e7–e13.
2010.PubMed/NCBI
|
|
14
|
Mao X, Yu Y, Boyd LK, et al: Distinct
genomic alterations in prostate cancers in Chinese and Western
populations suggest alternative pathways of prostate
carcinogenesis. Cancer Res. 70:5207–5212. 2010. View Article : Google Scholar
|
|
15
|
Miyagi Y, Sasaki T, Fujinami K, et al: ETS
family-associated gene fusions in Japanese prostate cancer:
analysis of 194 radical prostatectomy samples. Mod Pathol.
23:1492–1498. 2010. View Article : Google Scholar
|
|
16
|
Furusato B, van Leenders GJ, Trapman J, et
al: Immunohistochemical ETS-related gene detection in a Japanese
prostate cancer cohort: diagnostic use in Japanese prostate cancer
patients. Pathol Int. 61:409–414. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kimura T, Furusato B, Miki J, et al:
Expression of ERG oncoprotein is associated with a less aggressive
tumor phenotype in Japanese prostate cancer patients. Pathol Int.
62:742–748. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Suh JH, Park JW, Lee C and Moon KC: ERG
immunohistochemistry and clinicopathologic characteristics in
Korean prostate adenocarcinoma patients. Korean J Pathol.
46:423–428. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rawal S, Young D, Williams M, et al: Low
frequency of the ERG oncogene alterations in prostate cancer
patients from India. J Cancer. 4:468–472. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Qi M, Yang X, Zhang F, et al: ERG
rearrangement is associated with prostate cancer-related death in
Chinese prostate cancer patients. PLoS One. 9:e849592014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Petrovics G, Liu A, Shaheduzzaman S, et
al: Frequent overexpression of ETS-related gene-1 (ERG1) in
prostate cancer transcriptome. Oncogene. 24:3847–3852. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tomlins SA, Rhodes DR, Perner S, et al:
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in
prostate cancer. Science. 310:644–648. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dobi A, Sreenath T and Srivastava S:
Androgen-dependent oncogenic activation of ETS transcription
factors by recurrent gene fusions in prostate cancer: biological
and clinical implicationsAndrogen-Responsive Genes in Prostate
Cancer. WangZ: Springer; New York, NY: pp. 307–328. 2013,
View Article : Google Scholar
|
|
24
|
Sreenath TL, Dobi A, Petrovics G and
Srivastava S: Oncogenic activation of ERG: a predominant mechanism
in prostate cancer. J Carcinog. 10(37)2011.PubMed/NCBI
|
|
25
|
Furusato B, Tan SH, Young D, et al: ERG
oncoprotein expression in prostate cancer: clonal progression of
ERG-positive tumor cells and potential for ERG-based
stratification. Prostate Cancer Prostatic Dis. 13:228–237. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sun C, Dobi A, Mohamed A, et al:
TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer
activates C-MYC and abrogates prostate epithelial differentiation.
Oncogene. 27:5348–5353. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gupta S, Iljin K, Sara H, et al: FZD4 as a
mediator of ERG oncogene-induced WNT signaling and
epithelial-to-mesenchymal transition in human prostate cancer
cells. Cancer Res. 70:6735–6745. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Carver BS, Tran J, Gopalan A, et al:
Aberrant ERG expression cooperates with loss of PTEN to promote
cancer progression in the prostate. Nat Genet. 41:619–624. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
King JC, Xu J, Wongvipat J, et al:
Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in
prostate oncogenesis. Nat Genet. 41:524–526. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rahim S and Uren A: Emergence of ETS
transcription factors as diagnostic tools and therapeutic targets
in prostate cancer. Am J Transl Res. 5:254–268. 2013.PubMed/NCBI
|
|
31
|
Park K, Tomlins SA, Mudaliar KM, et al:
Antibody-based detection of ERG rearrangement-positive prostate
cancer. Neoplasia. 12:590–598. 2010.PubMed/NCBI
|
|
32
|
Braun M, Goltz D, Shaikhibrahim Z, et al:
ERG protein expression and genomic rearrangement status in primary
and metastatic prostate cancer - a comparative study of two
monoclonal antibodies. Prostate Cancer Prostatic Dis. 15:165–169.
2012. View Article : Google Scholar
|
|
33
|
Svensson MA, Perner S, Ohlson AL, et al: A
comparative study of ERG status assessment on DNA, mRNA, and
protein levels using unique samples from a Swedish biopsy cohort.
Appl Immunohistochem Mol Morphol. 22:136–141. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gsponer JR, Braun M, Scheble VJ, et al:
ERG rearrangement and protein expression in the progression to
castration-resistant prostate cancer. Prostate Cancer Prostatic
Dis. 17:126–131. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fontugne J, Lee D, Cantaloni C, et al:
Recurrent prostate cancer genomic alterations predict response to
brachytherapy treatment. Cancer Epidemiol Biomarkers Prev.
23:594–600. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hasan ARb: Statistica. Handbook Malaysia
2013. Department of Statistics; Malaysia: 2013
|
|
37
|
Attard G, Clark J, Ambroisine L, et al:
Duplication of the fusion of TMPRSS2 to ERG sequences identifies
fatal human prostate cancer. Oncogene. 27:253–263. 2008. View Article : Google Scholar
|
|
38
|
Rajput AB, Miller MA, De Luca A, et al:
Frequency of the TMPRSS2:ERG gene fusion is increased in moderate
to poorly differentiated prostate cancers. J Clin Pathol.
60:1238–1243. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Demichelis F, Fall K, Perner S, et al:
TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a
watchful waiting cohort. Oncogene. 26:4596–4599. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Darnel AD, Lafargue CJ, Vollmer RT, Corcos
J and Bismar TA: TMPRSS2-ERG fusion is frequently observed in
Gleason pattern 3 prostate cancer in a Canadian cohort. Cancer Biol
Ther. 8:125–130. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Perner S, Demichelis F, Beroukhim R, et
al: TMPRSS2:ERG fusion-associated deletions provide insight into
the heterogeneity of prostate cancer. Cancer Res. 66:8337–8341.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Mehra R, Tomlins SA, Shen R, et al:
Comprehensive assessment of TMPRSS2 and ETS family gene aberrations
in clinically localized prostate cancer. Mod Pathol. 20:538–544.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Schaefer G, Mosquera JM, Ramoner R, et al:
Distinct ERG rearrangement prevalence in prostate cancer: higher
frequency in young age and in low PSA prostate cancer. Prostate
Cancer Prostatic Dis. 16:132–138. 2013.PubMed/NCBI
|
|
44
|
Fromont G, Godet J, Peyret A, et al: 8q24
amplification is associated with Myc expression and prostate cancer
progression and is an independent predictor of recurrence after
radical prostatectomy. Hum Pathol. 44:1617–1623. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Gopalan A, Leversha MA, Satagopan JM, et
al: TMPRSS2-ERG gene fusion is not associated with outcome in
patients treated by prostatectomy. Cancer Res. 69:1400–1406. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Mosquera JM, Mehra R, Regan MM, et al:
Prevalence of TMPRSS2-ERG fusion prostate cancer among men
undergoing prostate biopsy in the United States. Clin Cancer Res.
15:4706–4711. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Setlur SR, Mertz KD, Hoshida Y, et al:
Estrogen-dependent signaling in a molecularly distinct subclass of
aggressive prostate cancer. J Natl Cancer Inst. 100:815–825. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Sboner A, Demichelis F, Calza S, et al:
Molecular sampling of prostate cancer: a dilemma for predicting
disease progression. BMC Med Genomics. 3(8)2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Hofer MD, Kuefer R, Maier C, et al:
Genome-wide linkage analysis of TMPRSS2-ERG fusion in familial
prostate cancer. Cancer Res. 69:640–646. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Xue L, Mao X, Ren G, et al: Chinese and
Western prostate cancers show alternate pathogenetic pathways in
association with ERG status. Am J Cancer Res. 2:736–744.
2012.PubMed/NCBI
|
